Talphera

Update in progress

TLPH (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings. Its lead candidate, Niyad, is a lyophilized nafamostat formulation that serves as a regional anticoagulant in extracorporeal circuits. LTX-608 is another nafamostat formulation for IV infusion targeting DIC, ARDS, acute pancreatitis, and potential antiviral use. It also develops Fedsyra and phenylephrine pre-filled syringes. Formerly AcelRx Pharmaceuticals, renamed January 2024. Founded 2005, based in San Mateo, California.

Company score

Sentiment: -0.02; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.00; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEOMr. Vincent J. Angotti
Founded2005
Employees12
Websitetalphera.com

Identifiers

ISINUS00444T2096
FIGIBBG0018YYFX7
CUSIP00444T209
CIK0001427925